Scott Rocklage Works with Expansion Therapeutics

Even though there may be individual effort involved in the turning of a vision into reality, endeavors that truly benefit mankind as a whole require teamwork. Expansion Therapeutics knows this matter of fact as a truth, through bringing together Series A financing into a portfolio designed to combat ailments based on genetics. At the top of the list of ailments to push back is Myotonic Dystrophy type I, which also goes by the name DM1.

 

This disorder is a major and leading cause for Muscular Dystrophy in adults, caused by RNA that have reached toxic levels. To reach its collective goal, Expansion Therapeutics continues to seek and manage financial resources to the tune of more than 50 million dollars. The collaborative effort of Expansion Therapeutics includes Sanofi Ventures, Kleiner Perkins, Novartis Venture Fund and 5AM Ventures all working together to end genetic disorders like DM1. This effort enjoys an assist from Alexandria Venture Investments and RA Capital Management.

 

The breakthroughs these organizations seek to make are based on the RNA molecules found in cells. DM1 and the ailment it causes effects the central nervous, hormonal, respiratory and gastrointestinal systems, as well as the heart and range-of-motion muscles. The medication that Expansion Therapeutics produces to treat diseases as a result of defective RNA are most important to patients and their families. This statement is particularly true because collective efforts of the organizations under the Expansion umbrella research expansion repeat disorders, which spread through heredity.

 

Every team has a set of leaders and key members who bring others together and make reaching the ultimate goal possible. In the case of Expansion Therapeutics, there are two names that stand out and deserve just a bit of notice. The first name to know is Matthew D. Disney Ph.D. who Performs as the main researcher for the scientific team. And while Disney makes sure that progress happens in the lab, 5AM Ventures Managing Partners, Scott M. Rocklage ensures future opportunities for the laboratory. When it comes to getting medications on the market, Rocklage has 30 years of experience to draw from.

 

Visit http://5amventures.com/team/scott-m-rocklage-phd/ to learn more.

Leave a Reply

Your email address will not be published. Required fields are marked *